Prothena (PRTA): Partner-Funded, Milestone-Rich Pipeline De-Risks Lead Programs and Supports Buy Rating

Andrew Fein, an analyst from H.C. Wainwright, maintained the Buy rating on Prothena. The associated price target remains the same with $30.00.

Andrew Fein has given his Buy rating due to a combination of factors, notably the recent $50M milestone payment from Novo Nordisk that underscores external confidence in Prothena’s lead ATTR-CM program, coramitug, and provides non-dilutive capital under a partnership that still holds close to $1B in potential milestones and future royalties. He highlights that Novo’s commitment to a large Phase 3 trial, following robust Phase 2 data showing meaningful NT-proBNP reductions and broad cardiac improvements, both validates the drug’s differentiated amyloid-depleting mechanism and materially de-risks the program.

At the same time, Fein points to parallel late-stage validation from additional partners, with Roche advancing prasinezumab into Phase 3 for Parkinson’s disease and the prospect of Bristol Myers Squibb triggering another milestone if PRX019 proceeds beyond Phase 1, collectively reinforcing confidence in Prothena’s discovery engine and partnership model. He argues that this milestone-rich, largely partner-funded development strategy, combined with the company’s lean cost base and the emerging CYTOPE and PRX012-TfR platforms, creates a favorable risk‑reward profile that supports a Buy recommendation on PRTA shares.

In another report released yesterday, TipRanks – Google also upgraded the stock to a Buy with a $10.50 price target.